Oncolytics Biotech Inc. (ONCY)

[onco_investor]

Article on the NCI sponsored Ovarian Cancer clinical trial at Ohio State University

http://www.standup2cancer.org/node/3436

David Cohn, MD specializes in gynecologic oncology at The Ohio State University Medical Center in Columbus, OH. His research areas include genetics of gynecologic oncology, prevention of gynecologic cancer, and vaccine therapy for ovarian cancer.

This trial is a monotherapy using a very aggressive IV as well as IP (IntraPeritoneal) infusions for 5 consecutive days every 28 days. Dr Cohn notes.....

"Our clinic is currently testing one of the most interesting, and potentially promising, cancer therapies to emerge in many years. The treatment, Reolysin, consists of a virus that attacks tumor cells while leaving normal cells unscathed. The treatment is being developed by Oncolytics Biotech, a Canadian biotechnology company."

......

This trial is one of 10 ongoing Phase II trials. Along with GBM, and Melanoma, this is a monotherapy approach potentially avoiding the side effects of chemo. We know that chemo or some kind of immune modulation seems to enhance the oncolytic effect of Reolysin so seeing good results out of this trial would be very encouraging.

onco_investor